Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1

作者：

Escudier, Bernard ^{[1
]}

Joly, Florence ^{[2
]}

Soria, Jean-Charles ^{[3
]}

机构：

[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

[2] Ctr Francois Baclesse, F-14076 Caen 05, France

[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France

来源：

BULLETIN DU CANCER | 2011年 / 98卷

关键词：

renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;

D O I：

10.1684/bdc.2011.1444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta

引用

页码：S3 / S6

页数：4

共 50 条

[21] Optimizing Patient Adherence to Targeted Therapies in Renal Cell Carcinoma: Practical Management Strategies in the Second-Line Setting
Creel, Patricia A.
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2014, 18 (06) : 694 - 700
[22] Management of side effects of targeted therapies in renal cancer: nephrological side effects
Izzedine, Hassan
Negrier, Sylvie
Neuzillet, Yann
Zini, Laurent
BULLETIN DU CANCER, 2011, 98 : S7 - S18
[23] Targeted Anti-Cancer Therapies for Renal Cancer
Robert J. Amato
Jaroslaw Jac
Drugs, 2006, 66 : 2161 - 2171
[24] Targeted Therapies in Advanced Renal Cell Cancer
Karaaslan, Sinan
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (03): : 210 - 213
[25] Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer
Seruga, B.
Gan, H. K.
Knox, J. J.
CURRENT ONCOLOGY, 2009, 16 : S54 - S61
[26] Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
Gore, M. E.
Larkin, J. M. G.
BRITISH JOURNAL OF CANCER, 2011, 104 (03) : 399 - 406
[27] New Treatments for Renal Cell Carcinoma: Targeted Therapies
Saylor, Philip J.
Michaelson, M. Dror
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (06): : 645 - 656
[28] Prognostic markers and targeted therapies for renal cell carcinoma
Gimenez, S. Elena
Secasan, Ciprian
Raman, Jay D.
FUTURE ONCOLOGY, 2009, 5 (02) : 197 - 205
[29] Management of side-effects of targeted therapies in renal cancer: endocrine side-effects and metabolic disorders
Caron, Philippe
Gravis, Gwenaelle
Oudard, Stephane
Pignot, Geraldine
BULLETIN DU CANCER, 2011, 98 : S47 - S59
[30] Targeted therapies for renal cell carcinoma
Villanueva, Mary Lee H.
Hauke, Ralph
TARGETED ONCOLOGY, 2007, 2 (01) : 7 - 16

← 1 2 3 4 5 →